JP2010529118A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529118A5
JP2010529118A5 JP2010511147A JP2010511147A JP2010529118A5 JP 2010529118 A5 JP2010529118 A5 JP 2010529118A5 JP 2010511147 A JP2010511147 A JP 2010511147A JP 2010511147 A JP2010511147 A JP 2010511147A JP 2010529118 A5 JP2010529118 A5 JP 2010529118A5
Authority
JP
Japan
Prior art keywords
hydrate
treatment
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010511147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529118A (ja
JP5416696B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2008/050666 external-priority patent/WO2008150233A1/en
Publication of JP2010529118A publication Critical patent/JP2010529118A/ja
Publication of JP2010529118A5 publication Critical patent/JP2010529118A5/ja
Application granted granted Critical
Publication of JP5416696B2 publication Critical patent/JP5416696B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010511147A 2007-06-07 2008-06-05 オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用 Expired - Fee Related JP5416696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94255307P 2007-06-07 2007-06-07
US60/942,553 2007-06-07
PCT/SE2008/050666 WO2008150233A1 (en) 2007-06-07 2008-06-05 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013235538A Division JP5815644B2 (ja) 2007-06-07 2013-11-14 オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用

Publications (3)

Publication Number Publication Date
JP2010529118A JP2010529118A (ja) 2010-08-26
JP2010529118A5 true JP2010529118A5 (en:Method) 2011-07-07
JP5416696B2 JP5416696B2 (ja) 2014-02-12

Family

ID=40093925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010511147A Expired - Fee Related JP5416696B2 (ja) 2007-06-07 2008-06-05 オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用
JP2013235538A Expired - Fee Related JP5815644B2 (ja) 2007-06-07 2013-11-14 オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013235538A Expired - Fee Related JP5815644B2 (ja) 2007-06-07 2013-11-14 オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用

Country Status (33)

Country Link
US (2) US8377940B2 (en:Method)
EP (2) EP2167502B3 (en:Method)
JP (2) JP5416696B2 (en:Method)
KR (2) KR20150116907A (en:Method)
CN (2) CN102977086B (en:Method)
AR (1) AR066882A1 (en:Method)
AU (1) AU2008260717B2 (en:Method)
BR (1) BRPI0812889A2 (en:Method)
CA (1) CA2690856C (en:Method)
CL (1) CL2008001667A1 (en:Method)
CO (1) CO6251287A2 (en:Method)
CY (2) CY1113422T1 (en:Method)
DK (2) DK2444399T3 (en:Method)
EC (1) ECSP109856A (en:Method)
ES (2) ES2393425T7 (en:Method)
HR (2) HRP20120909T4 (en:Method)
IL (1) IL202158A (en:Method)
ME (1) ME01488B (en:Method)
MX (1) MX2009013078A (en:Method)
MY (1) MY158066A (en:Method)
NZ (1) NZ582445A (en:Method)
PE (1) PE20090328A1 (en:Method)
PL (2) PL2444399T3 (en:Method)
PT (2) PT2167502E (en:Method)
RS (2) RS53845B1 (en:Method)
RU (2) RU2470931C2 (en:Method)
SA (1) SA08290344B1 (en:Method)
SI (2) SI2444399T1 (en:Method)
TW (1) TWI417100B (en:Method)
UA (1) UA99129C2 (en:Method)
UY (1) UY31124A1 (en:Method)
WO (1) WO2008150233A1 (en:Method)
ZA (1) ZA200908285B (en:Method)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009033703A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
US20130203995A1 (en) * 2010-01-07 2013-08-08 Astrazeneca Ab Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874
EP2563782A4 (en) * 2010-04-30 2013-09-04 Astrazeneca Ab POLYMORPHS OF POSITIVE ALLOSTERIC MODULATOR FOR METABOTROPIC GLUTAMATE RECEPTOR
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
PH12021552653A1 (en) 2014-01-21 2023-07-17 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CA2992700A1 (en) 2015-07-17 2017-01-26 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as hdac inhibitors
JPWO2017014170A1 (ja) * 2015-07-17 2018-04-26 武田薬品工業株式会社 複素環化合物
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
MX2022000693A (es) * 2019-07-18 2022-05-26 Abaxys Therapeutics Formulacion solida de un derivado de 1,2,4-oxadiazol.
GB2621323A (en) 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (en:Method) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
WO1998054135A1 (en) 1997-05-30 1998-12-03 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
MXPA00004940A (es) 1997-11-21 2002-10-17 Nps Pharma Inc Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
CA2417638A1 (en) 2000-07-31 2002-02-07 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
ATE538090T1 (de) * 2001-04-19 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 2-iminopyrrolidin- derivaten
HUP0401963A3 (en) 2001-08-09 2006-01-30 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US7521451B2 (en) * 2002-11-26 2009-04-21 Maruishi Pharmaceutical Co., Ltd. Isoindoline derivative
CA2519954A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
JP2007510629A (ja) 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー 新規ｍｃｈ受容体アンタゴニスト
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
BRPI0507495A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
US7902369B2 (en) 2004-03-05 2011-03-08 Banyu Pharmaceutical Co., Ltd. Diaryl-substituted five-membered heterocycle derivative
CN102558082B (zh) 2004-03-05 2015-09-30 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的制备中间体
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006047237A2 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
MX2007014444A (es) 2005-05-18 2008-04-21 Addex Pharmaceuticals Sa Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
CN101277934A (zh) * 2005-08-12 2008-10-01 阿斯利康(瑞典)有限公司 使代谢型谷氨酸-受体-增效的异吲哚酮
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
KR101121292B1 (ko) 2005-09-27 2012-04-13 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항제로서 옥사다이아졸일 피라졸로-피리미딘
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Similar Documents

Publication Publication Date Title
JP2010529118A5 (en:Method)
JP2012532874A5 (en:Method)
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
JP2010536849A5 (en:Method)
JP2011524850A5 (en:Method)
JP2013525444A5 (en:Method)
JP2015524444A5 (en:Method)
JP2010528011A5 (en:Method)
JP2013530958A5 (en:Method)
JP2012507538A5 (en:Method)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2010525055A5 (en:Method)
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
CY2017014I2 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
JP2014530220A5 (en:Method)
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
JP2008539267A5 (en:Method)
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
JP2011246469A5 (en:Method)
JP2007516193A5 (en:Method)
JP2013541583A5 (en:Method)
JP2012504560A5 (en:Method)
JP2009062388A5 (en:Method)
JP2010500284A5 (en:Method)